Biopharmaceuticals Contract Manufacturing Market To Reach $75.80 Billion By 2030

Biopharmaceuticals Contract Manufacturing Market Growth & Trends

The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to “COVID products” at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd. 

 Request a free sample copy or view the report summary: Biopharmaceuticals Contract Manufacturing Market Report

Biopharmaceuticals Contract Manufacturing Market Report Highlights

• Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development

• Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process

• Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development

• The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024

• Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition

Biopharmaceuticals Contract Manufacturing Market Segmentation

Grand View Research has segmented the biopharmaceuticals contract manufacturing market based on source, service, drug type, type, scale of operation, therapeutic area, and region:

Biopharmaceuticals Contract Manufacturing Source Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian

• Non-mammalian

Biopharmaceuticals Contract Manufacturing Service Outlook (Revenue, USD Million, 2018 - 2030)

• ProcessDevelopment

  • Downstream

  • Upstream

• Fill & Finish Operations

• Analytical & QC studies

• Packaging & Labelling

• Others

Biopharmaceuticals Contract Manufacturing Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Biologics

  • Monoclonal antibodies (mAbs)

  • Recombinant Proteins

  • Vaccines

  • Antisense, RNAi, & Molecular Therapy

  • Others

• Biosimilars

Biopharmaceuticals Contract Manufacturing Type Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Substance

• Finished Drug Product

Biopharmaceuticals Contract Manufacturing Scale of Operation Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical

• Commercial

Biopharmaceuticals Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Autoimmune Diseases

• Infectious Diseases

• Cardiovascular Diseases

• Metabolic Diseases

• Neurology

• Others

Biopharmaceuticals Contract Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • India

  • China

  • Japan

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Biopharmaceuticals Contract Manufacturing Market

• Boehringer Ingelheim GmbH

• Lonza

• Inno Biologics Sdn Bhd

• Rentschler Biotechnologie GmbH

• JRS PHARMA

• AGC Biologics

• ProBioGen

• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

• Toyobo Co. Ltd.

• Samsung Biologics

• Thermo Fisher Scientific, Inc.

• Binex Co., Ltd.

• WuXi Biologics

• AbbVie, Inc.

• ADMA Biologics, Inc.

• Catalent, Inc

• Cambrex Corporation

• Pfizer Inc.

• Siegfried Holding AG